



In re Application of:

Yehuda Assaraf et al.

Serial No.: 09/936,764

Filed: March 6, 2001

**For: METHOD OF AND KIT FOR ASSESSING RESPONSIVENESS OF CANCER PATIENTS TO ANTIFOLATE CHEMOTHERAPY**

**Examiner:**

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

5000

Group Art Unit: NA

Attorney  
Docket: 01/22501

## RESPONSE TO COMMUNICATION

Dear Sir:

This is a response to a notice to comply with requirements for patent applications containing nucleotide and/or amino acid sequence disclosures, sent February 7, 2002, a response to which is due, and being made, within two months. Please amend the above-identified application as follows:

**In the Specification:**

Please replace the Sequence Listing accompanying the application, with that attached herewith.

**REMARKS**


Enclosed please find:

- (i) a nucleotide and/or amino acid listing in a computer readable and paper forms; and
- (ii) a copy of the Notice.

***Statements***

The content of the paper and computer readable form are the same and include no new matter.

Respectfully submitted,



Sol Sheinbein  
Attorney for Applicant  
Registration No. 25,457

Date: March 10, 2002.

***Encl.:***

a nucleotide and/or amino acid listing in a computer readable form; and  
a copy of the Notice.



UNITED STATES PATENT AND TRADEMARK OFFICE

 Commissioner for Patents, Box PCT  
 United States Patent and Trademark Office  
 Washington, D.C. 20231  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/936,764	Yehuda Assaraf	01/22501

INTERNATIONAL APPLICATION NO.
-------------------------------

PCT/IL01/00212

I.A. FILING DATE	PRIORITY DATE
03/06/2001	03/06/2000

Sol Sheinbein  
 G E Enrich  
 Anthony Castorina  
 Suite 207 2001 Jefferson Davis Highway  
 Arlington, VA 22202

CONFIRMATION NO. 8693

371 FORMALITIES LETTER



\*OC000000007432817\*

Date Mailed: 02/07/2002 <sup>d</sup>

### NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated Office (37 CFR 1.494):

- U.S. Basic National Fees
- Priority Document
- Assignee Statement
- Biochemical Sequence Listing
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Request for Immediate Examination

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

**ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTH FROM THE DATE OF THIS NOTICE OR BY 22 or 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.**

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Additionally the following defects have been observed:

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- **APPLICANT MUST PROVIDE:**
  - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
  - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
  - For Rules Interpretation, call (703) 308-4216
  - To Purchase PatentIn Software, call (703) 306-2600
  - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)
- Additional claim fees of **\$270** as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

## SUMMARY OF FEES DUE:

Total additional fees required for this application is **\$270** for a Large Entity:

- Total additional claim fee(s) for this application is **\$270**
  - **\$270** for 15 total claims over 20.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

*No additional fees are due. This is a Small Entity* *Ad. Alkhar*

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

CHARITTA A BURT

Telephone: (703) 305-3734

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/936,764	PCT/IL01/00212	01/22501